JPRN-UMIN000020218已完成未知
Study on safety and efficacy of cetuximab in locally advanced, recurrent and/or metastatic oral cancer - Safety and efficacy of cetuximab in oral cancer
agasaki University0 个研究点目标入组 300 人开始时间: 2015年12月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients also applicable in one of the following are excluded as a target. 1. Cases with cetuximab treatment to December 20, 2012 or earlier. 2. Cases with complications in life prognosis in addition to oral cancer. 3. Cases with active double cancer. However, gastric cancer was cured by carcinoma in situ, or endoscopic mucosal resection that is judged to be cured with local treatment, esophageal cancer, colorectal cancer, such as pM it is not included in the activities of the overlapping cancer. 4. Other, patients principal investigator has determined to be inappropriate as a subject.
研究者
相似试验
进行中（未招募）
不适用
Efficacy of cetuximab in locally advanced or metastatic adenoid cystic carcinoma. Phase II.EUCTR2006-001694-23-HUational Institute of Oncology50
已完成
不适用
Safety assessment of treatment with cetuximab in metastatic colorectal cancer patientsMetastatic colorectal cancerMalignant neoplasm of other and ill-defined digestive organsCancerISRCTN34968597Institute of Oncology Ljubljana (Slovenia)250
进行中（未招募）
1 期
Randomised study of the efficacy of cetuximab rechallenge in patients with metastatic colorectal cancer (RAS wild-type) responding to first-line treatment with FOLFIRI plus cetuximabHistologically confirmed, UICC stage IV adenocarcinoma of the colon or rectum (metastatic colorectal cancer), primarily non-resectable or with surgery refused by the patientMedDRA version: 27.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003787-21-ATKlinikum der Ludwig-Maximilians-Univ. Münch , Klinikum Großhadern (vertreten durch die kaufmännische Direktion)700
进行中（未招募）
1 期
Randomised study of the efficacy of cetuximab rechallenge in patients with metastatic colorectal cancer (RAS wild-type) responding to first-line treatment with FOLFIRI plus cetuximabHistologically confirmed, UICC stage IV adenocarcinoma of the colon or rectum (metastatic colorectal cancer), primarily non-resectable or with surgery refused by the patientMedDRA version: 27.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003787-21-DEKlinikum der Ludwig-Maximilians-Univ. Münch , Klinikum Großhadern (vertreten durch die kaufmännische Direktion)700
进行中（未招募）
不适用
Randomized phase II feasibility study of Cetuximab combined with 4 cycles of TPF followed by platinum based chemo-radiation strategiesHistologically proven newly diagnosed unresectable squamous cellcarcinoma of the head and neckEUCTR2006-004189-14-HUEORTC50